FDA approves new combination treatment for acute myeloid leukemia
The FDA approved Rydapt (midostaurin) for treatment of adult patients with newly diagnosed acute myeloid leukemia who have a specific genetic mutation called FLT3, in combination with chemotherapy. The drug is approved for use with a companion diagnostic, the LeukoStrat CDx FLT3 Mutation Assay. April 28, 2017